潮州白癜风怎么治疗好得快潮州哪能治疗儿童白癜风,汕尾哪个白癜风医生最好,白癜风在汕头哪个地方推荐,潮州哪儿能检测白癜风,潮州白癜风哪里看有效果,潮州祛白癜风要挂什么科,汕尾头部白癜风能治好吗

More than 80 people were arrested after a third night of demonstrations in St. Louis over the acquittal of a former police officer who had been charged with first-degree murder.Arrests came after police officers were assaulted and "a concentrated area" was hit with vandalism including broken windows, broken sidewalk flower pots and overturned trash cans, acting Police Commissioner Larry O'Toole told media at a briefing late Sunday."Some criminals assaulted law enforcement officers and threw chemicals and rocks at them. All of the officers' injuries were minor or moderate. All will be returned to duty soon," O'Toole said. 636

MILWAUKEE -- If forcing a decisive Game 7 was the main victory for the Milwaukee Bucks at the BMO Harris Bradley Center Thursday night, mascot Bango's antics were certainly the "icing on the cake."During a timeout, Bango appeared with a fan in the crowd who was celebrating his birthday. The appearance was quickly derailed, however, by a braggadocious fan wearing a Boston Celtics t-shirt.  404

More than 40 percent of nonsmokers feel they should get 3-5 extra vacation days, according to a survey.E-cigarette maker Halo surveyed over 1,000 employed Americans about how fair they feel smoke breaks really are.Twenty-eight percent of smokers also felt that nonsmokers should be given three to five extra vacation days. However, the majority of smokers, 38 percent, didn't think nonsmokers should be given extra vacation days at all.The survey found that the average smoker spends roughly six days each year on smoke breaks at work. On average, Americans would give up smoking for 11 extra vacation days each year. Americans also believed companies should offer incentives for employees to quit smoking.The survey comes after nonsmoking employees at a Japanese agency received an additional six days of paid vacation time.  844

MOSCOW (AP) — Russia is boasting that it’s about to be the first country to approve a COVID-19 vaccine, with mass vaccinations planned as early as October using shots that are yet to complete clinical trials. But scientists worldwide are sounding the alarm that the headlong rush could backfire and point to ethical issues that undermine confidence in the Russian studies. Moscow sees a Sputnik-like propaganda victory, recalling the Soviet Union’s launch of the world’s first satellite in 1957. But the experimental COVID-19 shots began first-in-human testing on a few dozen people less than two months ago, and there’s no published scientific evidence yet backing Russia’s late entry to the global vaccine race, much less explaining why it should be considered a front-runner.“I’m worried that Russia is cutting corners so that the vaccine that will come out may be not just ineffective, but also unsafe,” said Lawrence Gostin, a global public health law expert at Georgetown University. “It doesn’t work that way. ... Trials come first. That’s really important.”According to Kirill Dmitriev, head of Russia’s Direct Investment Fund that bankrolled the effort, a vaccine developed by the Gamaleya research institute in Moscow may be approved in days, before scientists complete what’s called a Phase 3 study. That final-stage study, usually involving tens of thousands of people, is the only way to prove if an experimental vaccine is safe and really works. 1467

Moderna says that it will file for Emergency Use Authorization for its COVID-19 vaccine candidate after a primary efficacy analysis showed it to be 94% effective in preventing the virus.In a press release on Monday, Moderna said that a primary efficacy study of its vaccine candidate showed it to be 94% effective in preventing COVID-19 infection and that no participants who received the vaccine developed a severe case of the virus.According to Moderna's press release, of the 30,000 participants who took part in a Phase 3 trial, 196 have since contracted the virus. Of those participants, only 11 had received the vaccine — the other 185 had received a placebo. Only 30 people who took part in the trial have developed a severe case of the virus, all of whom received a placebo shot.The findings are consistent with efficacy figures released by Moderna just weeks ago. Moderna is the second U.S. company to seek Emergency Use Authorization for a COVID-19 vaccine. Pfizer submitted its application earlier this month.Like Pfizer's vaccine, the Moderna vaccine requires two shots that need to be taken 28 days apart. It also needs to be stored at ultra-cold temperatures before injection.Health experts say it is encouraging that there are multiple COVID-19 vaccine candidates that are nearing authorization, as the public will be less reliant on one vaccine in the unlikely event of safety issues.Experts like Dr. Anthony Fauci have said that there is a chance that some Americans in high-risk populations could begin receiving the vaccine in the coming weeks. However, COVID-19 vaccines won't be available for widespread use until the spring.Moderna's vaccine was funded in part by country singer Dolly Parton, who donated million to COVID-19 research at Vanderbilt University earlier this year. 1810